CDMO Upperton Pharma Solutions, which recently launched a new nasal delivery development platform, has announced that it will invest £15 million in a new 50,000 sq ft facility in Nottingham, UK that will include new laboratory space and 10 times more GMP manufacturing space than the company has currently. The new facility will also have the ability to handle highly potent APIs and controlled drugs, the company said.
According to Upperton, “the increased capacity will enable Upperton to continue to meet the growing demand for its oral, nasal and pulmonary dosage form development and GMP manufacturing services, as well as expand its offering to support larger scale, later stage development.” The company said that it expects to hire an additional 100 employees for the new site, which is expected to be complete by the end of 2023.
Upperton CEO Nikki Whitfield commented, “We are excited to be building new formulation development and analytical laboratories alongside the GMP facility to ensure our operations and capabilities remain state of the art. The new facilities will enable us to increase our current development and manufacturing capacity as well as expand our solid dose and spray drying offerings to address the growing needs of our customers. We enjoy close relationships with our clients and want to maintain the scientific and manufacturing support provided in the early stages of their product development through to late stage and commercial.”
Read the Upperton Pharma Solutions press release.
